TRVI SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

NEWForm 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 9, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 6, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 5, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 17, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 13, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 7, 2025

News

TYPE

HEADLINE

FILED AT

8-K

NEWTrevi Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates

Nov 9, 2026

8-K

Trevi Therapeutics Announces Financial Results for the Second Quarter Ended June 30, 2026

Aug 6, 2026

8-K

Trevi Therapeutics Announces Results of 2026 Annual Meeting of Stockholders

Jun 4, 2026

8-K

Trevi Therapeutics Reports Q1 2026 Financial Results and Business Updates

May 5, 2026

8-K

Trevi Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock

Apr 17, 2026

8-K

Trevi Therapeutics Reports 2025 Financial Results and Provides Clinical Development Updates for Haduvio™

Mar 17, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

REGISTERED OFFERING

Apr 17, 2026

424B5

PENDING FIXED PRICE OFFERING | Offering amount: $150,000,000 | Bank: Morgan Stanley, Leerink Partners, Cantor, Stifel, Oppenheimer & Co.

Apr 16, 2026

424B5

REGISTERED OFFERING

Jun 4, 2025

424B5

SHELF OFFERING | Offering amount: $100,000,000 | Bank: MORGAN STANLEY, LEERINK PARTNERS, STIFEL, CANTOR

Jun 2, 2025

424B5

Form 424B5 - Prospectus [Rule 424(b)(5)]

Dec 16, 2024

424B5

SHELF OFFERING | Shares amount: 14,252,670 | Share price: $1.93 | Warrants amount: 14,247,330 | Offering amount: $54,990,753.00

Sep 23, 2022

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Aug 6, 2026

S-3ASR

SHARE RESALE REGISTRATION | Offering amount: $200,000,000

Nov 13, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Aug 7, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 18, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 20, 2024

S-3/A

SHELF | ATM | Offering amount: $200,000,000.00 EFFECTIVE

Aug 11, 2023

Proxies

TYPE

HEADLINE

FILED AT

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 21, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 21, 2026

PRE 14A

Form PRE 14A - Other preliminary proxy statements

Apr 10, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 29, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 29, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 26, 2024

Ownerships

TYPE

HEADLINE

FILED AT

SCHEDULE 13G/A

BlackRock, Inc. (Filed by)

Oct 27, 2026

Heffernan Michael Thomas (Reporting)

Sep 17, 2026

144

Form 144 - Report of proposed sale of securities

Sep 15, 2026

SCHEDULE 13G/A

FMR LLC (Filed by)

Aug 6, 2026

Mathers Edward T (Reporting)

Jun 4, 2026

Colangelo Dominick (Reporting)

Jun 4, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Aug 16, 2023

CORRESP

Form CORRESP - Correspondence

Aug 14, 2023

LETTER

Form UPLOAD - SEC-generated letter

Jul 5, 2023

EFFECT

Form EFFECT - Notice of Effectiveness

May 12, 2022

CORRESP

Form CORRESP - Correspondence

May 9, 2022

LETTER

Form UPLOAD - SEC-generated letter

May 6, 2022

Trevi Therapeutics, Inc. TRVI · SEC Filings